Intrabio Ltd

Intrabio Ltd is a small, active company based in London, UK, founded nine years ago in 2015. With £9,999,939 in assets and a virtual address, it employs just four people and is managed by two directors—although no owners are officially listed. The company operates in the professional, scientific, and technical activities sector. It’s a bit of an odd one, acting as an irregular importer of pharmaceutical products (just one month of activity in 2017) and a regular exporter of miscellaneous chemical products (three months of activity, last recorded in 2021).

The company's website paints a very different picture. Intrabio positions itself as a leader in discovering and developing innovative drugs for rare neurodegenerative diseases. It focuses heavily on its lead drug candidate, IB1001, detailing clinical trials, publications in leading medical journals (like the New England Journal of Medicine), and even a US FDA acceptance of its NDA. The site is very professional, with dedicated sections for patients, providers, and even expanded access policies—a clear indication of a company focused on research and development, not just chemical trading. It's a little confusing how the trading activities fit into this picture.

Financially, Intrabio Ltd presents a mixed bag. While cash reserves increased by a healthy 35% to £830,000, current assets have seen a significant jump, rising by 540% to £10 million. However, creditors have also ballooned by 52%, reaching £22 million. Trade debtors have increased dramatically, too, jumping 880% to £9.2 million. Perhaps most concerning is the sharp decline in equity, with retained earnings dropping 8.3% to -£12 million. The company's small size (meeting two of three conditions for a small company) means it’s likely exempt from an audit, and the figures are unaudited. Employee numbers have also fallen, decreasing by 50% to just two people.

In short, Intrabio Ltd appears to be burning through cash despite its impressive research pipeline. The large increase in creditors and debtors suggests it’s relying on borrowing and extending credit terms to keep operating—a common pattern for startups in high-cost sectors like pharmaceuticals. It’s possible the company is reinvesting heavily in research and development, but the financial trends raise questions about its long-term sustainability.

Registered in England/Wales under the registration number 09851769, with a registered address at NW3 6BP, United Kingdom, London, Summit House, 170 Finchley Road.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.